findmyKOL
Clinical trialNCT07710534Not, yet, recruitingPhase 2Interventional

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

SponsorVirginia Commonwealth UniversityEnrollment40High Risk Myelodysplastic SyndromeHigh Risk Myeloproliferative NeoplasmsRelapsed / Refractory AML
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-center randomized phase 2 open-label clinical trial.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Virginia Commonwealth University

    Richmond, Virginia, United States

    Keri Maher, DO

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine plus venetoclaxDecitabine-cedazuridine plus venetoclax
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2026
Primary completion
30 Sept 2031
Completion
31 Dec 2033
Last update posted
17 Jul 2026
Registered enrollment
40
Registry id
NCT07710534
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.